甲磺酸阿帕替尼联合XELOX方案一线应用于晚期胃癌的疗效与安全性评价

章海斌; 丁晓娇; 王练; 王子安

doi:10.13898/j.cnki.issn.1000-2200.2023.02.007

甲磺酸阿帕替尼联合XELOX方案一线应用于晚期胃癌的疗效与安全性评价

Evaluation of the efficacy and safety of apatinib mesylate combined with XELOX regimen in the first-line treatment of advanced gastric cancer

摘要

摘要:
目的对比XELOX方案联合或不联合甲磺酸阿帕替尼在晚期胃癌一线治疗中的疗效与安全性差异。
方法回顾性分析65例不可切除的晚期胃癌病人的临床病例资料，其中35例一线接受甲磺酸阿帕替尼联合XELOX方案化疗的病人纳入阿帕替尼联合化疗组，30例一线接受XELOX方案化疗的病人纳入化疗组。在治疗开始前及经过2周期治疗结束后，评估疗效，统计病人生存时间及不良反应情况。
结果阿帕替尼联合化疗组的近期疗效客观缓解率（60.00% vs 23.33%）、疾病控制率（88.57% vs 50.00%）均优于化疗组（P < 0.01）。截至随访时间，阿帕替尼联合化疗组的中位无进展生存时间为8.9个月（95%CI：0.679~2.382），中位总生存时间为15个月（95%CI：0.689~2.699）。化疗组的中位无进展生存时间为7个月（95%CI：0.420~1.474），中位总生存时间为11个月（95%CI：0.371~1.451），阿帕替尼联合化疗组的生存时间优于化疗组（P < 0.05）。2组不良反应相似，阿帕替尼联合化疗组任意级别不良反应发生率与化疗组的差异均无统计学意义（P>0.05）。
结论甲磺酸阿帕替尼联合XELOX方案是晚期胃癌一线治疗安全有效的选择。

Abstract:
ObjectiveTo compare the efficacy and safety of XELOX regimen with or without apatinib mesylate in the first-line treatment of advanced gastric cancer.
MethodsThe clinical data of 65 patients with unresectable advanced gastric cancer were retrospectively analyzed.Thirty-five patients who received first-line chemotherapy with apatinib mesylate combined with XELOX regimen were included in the apatinib combined chemotherapy group, and 30 patients who received first-line chemotherapy with XELOX regimen were included in the chemotherapy group.Before the start of treatment and after the end of two cycles of treatment, the curative effect was evaluated, and the survival time and adverse reactions of patients were counted.
ResultsThe short-term objective response rate (60.00% vs 23.33%) and disease control rate (88.57% vs 50.00%) of the apatinib combined chemotherapy group were better than those of the chemotherapy group (P < 0.01).By the time of follow-up, the median progression free survival was 8.9 months (95%CI: 0.679-2.382) and the median overall survival was 15 months (95%CI: 0.689-2.699) in the apatinib combined chemotherapy group.The median progression free survival was 7 months (95%CI: 0.420-1.474) and the median overall survival was 11 months (95%CI: 0.371-1.451) in the chemotherapy group.The survival time of apatinib combined with chemotherapy group was better than that of chemotherapy group (P < 0.05).The adverse reactions of the two groups were similar.There was no significant difference in the incidence of any level of adverse reactions between the apatinib combined chemotherapy group and the chemotherapy group(P>0.05).
ConclusionsApatinib mesylate combined with XELOX is a safe and effective option for the first-line treatment of advanced gastric cancer.

HTML全文

参考文献(13)

施引文献

资源附件(0)